GENES |
Normal Expression |
Altered Expression |
P Value |
GENES |
Normal Expression |
Altered Expression |
P Value |
BRCA1
ER/PR+
ER/PR- |
8(100%)
11(100%)
|
0(0%)
0(10%)
|
0.882 |
BRCA1
ER/PR+
ER/PR- |
7(87.5%)
10(90%)
|
1(12.5%)
1(10%)
|
0.811 |
BRCA2
ER/PR+
ER/PR- |
8(100%)
11(100%)
|
0(0%)
8(0%)
|
0.096 |
BRCA2
ER/PR+
ER/PR- |
5(62.5%)
9(81.8%)
|
3(37.5%)
2(18.1%)
|
0.353 |
HER2
ER/PR+
ER/PR- |
5(62.5%)
6(54.54%)
|
3(37.5%)
5(45.45%)
|
0.729 |
HER2
ER/PR+
ER/PR- |
1(12.5%)
4(36.3%)
|
7(87.5%)
7(63.63%)
|
0.263
|
ER
ER/PR+
ER/PR- |
8(100%)
10(90%)
|
0(0%)
1(10%)
|
0.601 |
ER
ER/PR+
ER/PR- |
0(0%)
10(90%)
|
8(100%)
1(10%)
|
0.004
|
PR
ER/PR+
ER/PR- |
6(75%)
10(90%)
|
2(25%)
1(10%)
|
0.365 |
PR
ER/PR+
ER/PR- |
0(0%)
10(90%)
|
8(100%)
1(10%)
|
0.004
|
PI3KCA
ER/PR+
ER/PR- |
5(62.5%)
9(81.8%)
|
3(37.5%)
2(18.1%)
|
0.353 |
PI3KCA
ER/PR+
ER/PR- |
5(62.5%)
5(45.4%)
|
3(37.5%)
6(54.5%)
|
0.465
|
EGFR
ER/PR+
ER/PR- |
5(62.5%)
6(54.5%)
|
3(37.5%)
5(45.4%)
|
0.729 |
EGFR
ER/PR+
ER/PR- |
3(37.5%)
5(45.4%)
|
5(62.5%)
6(54.5%)
|
0.465
|
MET
ER/PR+
ER/PR- |
7(87.5%)
8(72.7%)
|
1(12.5%)
3(27.2%)
|
0.445 |
MET
ER/PR+
ER/PR- |
2(25%)
7(63.6%)
|
6(75%)
4(36.3%)
|
0.107
|
PTEN
ER/PR+
ER/PR- |
1(12.5%)
4(36.36%)
|
7(87.5%)
7(63.3%)
|
0.263 |
PTEN
ER/PR+
ER/PR- |
7(87.5%)
6(54.5%)
|
1(12.5%)
5(45.4%)
|
0.151
|
BRAF
ER/PR+
ER/PR- |
8(100%)
11(100%)
|
0(0%)
0(0%)
|
0.882 |
BRAF
ER/PR+
ER/PR- |
5(62.5%)
9(81.8%)
|
3(37.5%)
2(16.6%)
|
0.353 |
|